244 related articles for article (PubMed ID: 35530291)
1. Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.
Su CW; Hou MM; Huang PW; Chou YC; Huang BS; Tseng JH; Hsu CW; Chang TC; Lin SM; Lin CC
Am J Cancer Res; 2022; 12(4):1606-1620. PubMed ID: 35530291
[TBL] [Abstract][Full Text] [Related]
2. Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma.
Yu JI; Yoo GS; Cho S; Jung SH; Han Y; Park S; Lee B; Kang W; Sinn DH; Paik YH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Park HC
Radiat Oncol J; 2018 Mar; 36(1):25-34. PubMed ID: 29580046
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis.
Xian F; Wu J; Zhong L; Xu G
Medicine (Baltimore); 2023 Mar; 102(10):e33204. PubMed ID: 36897735
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
Front Immunol; 2022; 13():801909. PubMed ID: 35309350
[TBL] [Abstract][Full Text] [Related]
5. Proton beam stereotactic body radiotherapy and hypofractionated therapy with pencil beam scanning is safe and effective for advanced hepatocellular carcinoma and intrahepatic cholangiocarcinoma: A single center experience.
Yang AH; Urrunaga NH; Siddiqui O; Wu A; Schliep M; Mossahebi S; Shetty K; Regine WF; Molitoris JK; Lominadze Z
J Radiosurg SBRT; 2023; 9(1):43-52. PubMed ID: 38029012
[TBL] [Abstract][Full Text] [Related]
6. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Pfister D; Núñez NG; Pinyol R; Govaere O; Pinter M; Szydlowska M; Gupta R; Qiu M; Deczkowska A; Weiner A; Müller F; Sinha A; Friebel E; Engleitner T; Lenggenhager D; Moncsek A; Heide D; Stirm K; Kosla J; Kotsiliti E; Leone V; Dudek M; Yousuf S; Inverso D; Singh I; Teijeiro A; Castet F; Montironi C; Haber PK; Tiniakos D; Bedossa P; Cockell S; Younes R; Vacca M; Marra F; Schattenberg JM; Allison M; Bugianesi E; Ratziu V; Pressiani T; D'Alessio A; Personeni N; Rimassa L; Daly AK; Scheiner B; Pomej K; Kirstein MM; Vogel A; Peck-Radosavljevic M; Hucke F; Finkelmeier F; Waidmann O; Trojan J; Schulze K; Wege H; Koch S; Weinmann A; Bueter M; Rössler F; Siebenhüner A; De Dosso S; Mallm JP; Umansky V; Jugold M; Luedde T; Schietinger A; Schirmacher P; Emu B; Augustin HG; Billeter A; Müller-Stich B; Kikuchi H; Duda DG; Kütting F; Waldschmidt DT; Ebert MP; Rahbari N; Mei HE; Schulz AR; Ringelhan M; Malek N; Spahn S; Bitzer M; Ruiz de Galarreta M; Lujambio A; Dufour JF; Marron TU; Kaseb A; Kudo M; Huang YH; Djouder N; Wolter K; Zender L; Marche PN; Decaens T; Pinato DJ; Rad R; Mertens JC; Weber A; Unger K; Meissner F; Roth S; Jilkova ZM; Claassen M; Anstee QM; Amit I; Knolle P; Becher B; Llovet JM; Heikenwalder M
Nature; 2021 Apr; 592(7854):450-456. PubMed ID: 33762733
[TBL] [Abstract][Full Text] [Related]
7. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial.
Kim TH; Koh YH; Kim BH; Kim MJ; Lee JH; Park B; Park JW
J Hepatol; 2021 Mar; 74(3):603-612. PubMed ID: 33031846
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.
Li JX; Deng WX; Huang ST; Lin XF; Long MY; Zhang J; Su TS; Li LQ; Pang YD; Liang CF; Zhou HM; Lu HY; Liang SX; Xiang BD
Radiat Oncol; 2022 Jun; 17(1):106. PubMed ID: 35690773
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis.
Jin Y; Wei J; Weng Y; Feng J; Xu Z; Wang P; Cui X; Chen X; Wang J; Peng M
Front Oncol; 2022; 12():732814. PubMed ID: 35280727
[TBL] [Abstract][Full Text] [Related]
10. Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma.
Kang E; Martinez M; Moisander-Joyce H; Saenger YM; Griesemer AD; Kato T; Yamashiro DJ; Remotti H; Gartrell RD
Pediatr Transplant; 2022 May; 26(3):e14209. PubMed ID: 34907641
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy.
Liu J; Chen Z; Li Y; Zhao W; Wu J; Zhang Z
Front Pharmacol; 2021; 12():731798. PubMed ID: 34539412
[TBL] [Abstract][Full Text] [Related]
12. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
[TBL] [Abstract][Full Text] [Related]
13. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
Tzeng A; Diaz-Montero CM; Rayman PA; Kim JS; Pavicic PG; Finke JH; Barata PC; Lamenza M; Devonshire S; Schach K; Emamekhoo H; Ernstoff MS; Hoimes CJ; Rini BI; Garcia JA; Gilligan TD; Ornstein MC; Grivas P
Target Oncol; 2018 Oct; 13(5):599-609. PubMed ID: 30267200
[TBL] [Abstract][Full Text] [Related]
14. A Novel Nomogram to Predict Prognosis of Advanced Hepatocellular Carcinoma Treated with Intensity-Modulated Radiotherapy Plus Anti-PD1.
He M; Liang C; Pang Y; Jiang M; Long M; Yao Z; Wang X; Zhang R; Wu Q; Liang S; Li J
J Hepatocell Carcinoma; 2024; 11():913-925. PubMed ID: 38799002
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma.
Kim TH; Park JW; Kim BH; Oh ES; Youn SH; Moon SH; Kim SS; Woo SM; Koh YH; Lee WJ; Kim DY
Front Oncol; 2020; 10():542. PubMed ID: 32411594
[No Abstract] [Full Text] [Related]
16. Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study.
Sun Y; Jiang L; Wen T; Guo X; Shao X; Qu H; Chen X; Song Y; Wang F; Qu X; Li Z
Front Pharmacol; 2021; 12():670900. PubMed ID: 34489691
[TBL] [Abstract][Full Text] [Related]
17. Combination of Lenvatinib and Proton Beam Therapy in the Management of Patients With Advanced Hepatocellular Carcinoma.
Cheng JY; Huang BS; Chen YY; Wang CC; Chen YH
Anticancer Res; 2023 Mar; 43(3):1361-1371. PubMed ID: 36854503
[TBL] [Abstract][Full Text] [Related]
18. PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review).
Tang Q; Zhao S; Zhou N; He J; Zu L; Liu T; Song Z; Chen J; Peng L; Xu S
Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36866750
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of the Radiotherapy for Liver Cancer: Assessment of Local Controllability and its Role in Multidisciplinary Therapy.
Ohkoshi-Yamada M; Kamimura K; Shibata O; Morita S; Kaidu M; Nakano T; Maruyama K; Ota A; Saito H; Yamana N; Oshikane T; Goto Y; Yoshimura N; Tanabe S; Nakano H; Sakai M; Tanaka Y; Koseki Y; Arao Y; Abe H; Setsu T; Sakamaki A; Yokoo T; Kamimura H; Aoyama H; Terai S
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066141
[TBL] [Abstract][Full Text] [Related]
20. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
